

MANUFACTURING DEVELOPMENT PROJECT WITH CSIRO ADVANCES TO STAGE 3

- **New research project focuses on further improving the synthesis of Flavocide™**
- **Initial phases reduced cost and complexity of manufacturing Flavocide™ while improving yield**
- **Project to be managed by CSIRO as Stage 3 of Bio-Gene's manufacturing development strategy**
- **Awarded \$50K as part of successful government research grant application**

Bio-Gene Technology Limited (ASX: BGT, "Bio-Gene" or "the Company") is pleased to announce the advancement of its Flavocide™ manufacturing development project with CSIRO to Stage 3 after successful results in the initial phases of the program.

In the work performed to date, CSIRO was able to reduce the cost and complexity of manufacturing Flavocide™ as well as a key intermediate, where yield improvements were up to 60% greater than previously obtained. This work, undertaken through the CSIRO Kick-Start program, also discovered an alternative method of manufacturing Flavocide™ which not only gives Bio-Gene novel IP around the process, but provides an alternative supply chain for the product.

Stage 3 builds upon the discoveries of the earlier work with the aim to continue to improve yield, purity, and cost of Flavocide™ and the key intermediate, as well as reduce waste material from the process. The research project will be performed by CSIRO's industrial chemistry scientists at their Clayton facility.

The project was initially undertaken to further evaluate and improve the yield and synthesis of Bio-Gene's key Flavocide™ compound. It is also targeting scale up of the molecule and specific intermediates before translating these research findings into commercially adaptable processes and protocols.

To supplement the next stage of the project, Bio-Gene received approval for a government funded Innovations Connections grant of \$50,000. The grant was facilitated by CSIRO's SME Connect team and the program provides small and medium sized businesses with access to expert technology advice to address technology and knowledge gaps, and collaborate with the research sector in developing new ideas with commercial potential.

Dr. Adam Meyer, Principal Research Scientist at CSIRO who led the research commented: "We were very pleased with the outcome of Stages 1 and 2 of this project. Not only have the results demonstrated considerable improvements to the process and cost of manufacturing Flavocide™, it has given us the direction for the Stage 3 work, which is vital to ensure we are focusing on the best areas to achieve further significant improvements."

Bio-Gene CEO, Richard Jagger commented: "Manufacturing of the molecule on a commercial scale is a very important step to ensure the viability of our technology. The CSIRO scientists assigned to the project are experts in their field, and have already made significant advances towards developing an optimised process for commercial production. In doing so, they have created significant intellectual property for Bio-Gene. To be able to secure a grant to fund a substantial component of the costs of this project with non-dilutive funds is an added bonus.

"The commercially viable synthesis of Flavocide™ is important for large scale applications of our technology. This work will further assure our future commercial partners of Bio-Gene's commitment to the technology and the feasibility of manufacture and supply."

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Media/investor relations:

Matthew Wright
NWR Communications
P: 0451 896 420
E: matt@nwrcommunications.com.au

About Bio-Gene Technology Ltd

Bio-Gene is an Australian AgTech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

About CSIRO

CSIRO, the Commonwealth Scientific and Industrial Research Organisation, is Australia's national science agency and one of the largest and most diverse research agencies in the world. Its innovations contribute billions of dollars to the Australian economy every year. As the largest patent holder in the nation, CSIRO's wealth of intellectual property has led to more than 150 spin-off companies. For more information visit www.csiro.au